FibroGen (NASDAQ:FGEN) Issues Quarterly Earnings Results

FibroGen (NASDAQ:FGEN) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08), Zacks reports. The firm had revenue of $3.14 million for the quarter, compared to analyst estimates of $24.91 million.

FibroGen Stock Performance

Shares of NASDAQ:FGEN opened at $0.35 on Wednesday. The company has a fifty day moving average of $0.50 and a 200-day moving average of $0.43. The company has a market capitalization of $35.07 million, a PE ratio of -0.28 and a beta of 0.82. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.80.

Analyst Upgrades and Downgrades

FGEN has been the subject of several research analyst reports. StockNews.com initiated coverage on shares of FibroGen in a research report on Friday, March 14th. They set a “hold” rating for the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of FibroGen in a research report on Tuesday.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.